[I-].[C:2]([O:6][C:7]([NH:9][CH:10]1[CH2:14][CH2:13][N:12]([C:15]([N:17]2[CH:21]=[CH:20][N+](C)=[CH:18]2)=[O:16])[CH2:11]1)=[O:8])([CH3:5])([CH3:4])[CH3:3].[F:23][C:24]([F:36])([F:35])[C:25]1[CH:26]=[N:27][C:28]2CCNC[C:33]=2[CH:34]=1.CCN(CC)CC>C(Cl)Cl>[C:2]([O:6][C:7](=[O:8])[NH:9][CH:10]1[CH2:14][CH2:13][N:12]([C:15]([N:17]2[CH2:18][CH2:33][C:28]3[N:27]=[CH:26][C:25]([C:24]([F:36])([F:35])[F:23])=[CH:34][C:20]=3[CH2:21]2)=[O:16])[CH2:11]1)([CH3:3])([CH3:4])[CH3:5]To a solution of 3-(3-tert-butoxycarbonylamino-pyrrolidine-1-carbonyl)-1-methyl-3H-imidazol-1-ium iodide (preparation #4) (7.81 g, 18.5 mmol) in DCM (70 mL) was added 3-trifluoromethyl-5,6,7,8-tetrahydro-[1,6]naphthyridine (3.74 g, 18.5 mmol) and Et3N (2.6 mL, 18.5 mmol) and the reaction mixture was stirred at ambient temperature for about 16 h. Additional Et3N (1.5 mL, 10.7 mmol) was added and the reaction mixture was stirred at ambient temperature for about 16 h. The reaction mixture was concentrated in vacuo and the residue was purified by flash chromatography on silica gel using 5% MeOH/DCM as the mobile phase to give [1-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridine-6-carbonyl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester (4.91 g, 64%). RP-HPLC (Table 1, Method a) Rt 2.37 min; m/z: (M+H)+ 415.